APASL 2013---The 23th Conference of the Asian Pacific Association for the Study of the Liver
Poster Presentation(Abstract NO 744)
Hepatology
International. 2013, 7(Suppl 1):s202.
Bang-Fu Wu1,2, Jiang-Ying Yang2,
Ya-Lin Zhang3, Yong Liu1, Hui-Hua Zhou3,
Xuan-Qin Wang1, Fang-Qin Li1, Chun-Qiong Hou3,
Xue-Song Li1, Xiang-Hua Huang1, Zheng-Sheng Xiao1,
Ming Yang1, Fu-Xin Lin3, Yan-Ping Fu3, Shuo
Zheng3, Wei Chen3, Yun Zhou2, Jun Yang2,
Xin-He Wan1, Hui Huang1
1.Gastroenterology and Hepatology Center, Southern
Medical University Renkang Hospital, Houjie Dongxi Road, No.88, Dongguan
523952, China
2 Guangzhou Pubang Bio-Immunological Tech
Research Institute, Kezhu Road, No.232-2, Room 205, Guangzhou Science City,
Luogang District, Guangzhou 510663, China
3 Gastroenterology and Hepatology Center, Tongji Medical College Affiliated
Dongguan Hospital, Huazhong University of Science and Technology, Liaobu
Southwest Road, No.171-175, Dongguan 523416, China
Background/Aims: To observe the clinical efficacy of anti-HBV-DC vaccine, the dendritic
cells originating from peripheral blood mononuclear cells(PBMC) sensitized by
HBsAg, in combination with lamivudine and thymosin-α1, in HBeAg positive
chronic hepatitis B(CHB) patients.
Methods: 36 patients were recruited in the trial including 18 with
ALT≤2ULN and 18 with ALT>2ULN. PBMCs obtained from 50ml of heparinized
peripheral blood through density gradient centrifuge and adherence method were
proliferated under the induction by GM-CSF and IL-4, and sensitized with the
stock of hepatitis B vaccine containing 30µg HBsAg on day 5 and with hepatitis
B vaccine commercially available containing 20µg HBsAg on day 6. anti-HBV-DC
vaccine was harvested on day 7 and injected, half hypodermically and half
intravenously, to the patient once every two weeks for 12 practices
applications totally. Lamivudine was taken 100mg daily, and thymosin-α1 1.6mg
was injected hypodermically twice a week. HBVM(TRFIA) and HBVDNA and ALT were
evaluated at week 0, 4, 12, and 24.
Results: Mean of HBsAg, HBeAg, HBVDNA
and ATL decreased significantly, while mean of HBeAb increased obviously after
therapy of 4, 12 and 24 weeks. At week 4, 12 and 24, HBeAg negative conversion
rate were 44.44%(16/36), 52.78(19/39) and 61.11%(22/36) respectively, HBeAb
positive conversion rate were 33.33%(12/36), 44.44%(16/36) and 50.00%(18/36),
HBeAg seroconversion rate were 27.78%(10/36), 44.44%(16/36) and 50.00%(18/36),
HBVDNA negative conversion rate were 38.89%(14/36), 44.44%(16/36), and
66.67%(24/36), ALT normalization rate were 19.44%(7/36), 55.56%(20/36) and
72.22%(26/36), and HBeAg seroconversion rate was 22.22%(4/18), 33.33%(6/18) and
33.33%(6/18) in patients with ALT≤2ULN, and 33.33%(6/18), 55.56%(10/18) and
66.67%(12/18) in those with ALT>2ULN.
Conclusions: anti-HBV-DC vaccine in combination with lamivudine and
thymosin-α1 can be considered as a safe approach with high efficacy for HBeAg
positive CHB patients, which may effectively inhibit the viral replication,
lower rapidly HBsAg, HBeAg and HBVDNA, improve the production of HBeAb, and
increase the HBeAg seroconversion rate.
Author Keywords: Dendritic cells (DC);
Hepatitis B virus (HBV); Chronic hepatitis B (CHB); Vaccine
|
